drugset
drugset / Trial / NCT07478822

A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity

NCT07478822 ↗

Phase 3 Recruiting 300 enrolled Chongqing Claruvis Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase III clinical study to evaluate the long-term safety and efficacy of multiple treatments with recombinant botulinum toxin type A (YY001) for injection in adult upper limb spasticity

Timeline

Start
2026-03-27
Primary completion
2027-06-01
Completion
2027-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Recombinant Botulinum Toxin Type A Protein / enzyme biologic 200 iu Intramuscular
Subject Recombinant Botulinum Toxin Type A Protein / enzyme biologic 400 iu Intramuscular

Indications

No indication recorded.